홈 › 만성 림프구성 백혈병 › 노스캐롤라이나 › Durham
NC Durham의 만성 림프구성 백혈병 임상 시험
만성 림프구성 백혈병 관련 연구 27개가 Durham 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
피험자 모집 중3상
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10마일 거리
- University of North Carolina-Hillsborough Campus, Hillsborough · 13마일 거리
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
피험자 모집 중3상
- University of North Carolina At Chapel Hill, Chapel Hill · 10마일 거리
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
피험자 모집 중3상
- Duke University Medical Center, Durham
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
피험자 모집 중3상
- Duke University Medical Center, Durham
- University of North Carolina At Chapel Hill, Chapel Hill · 10마일 거리
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
피험자 모집 중3상
- Duke University, Durham
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
피험자 모집 중2상
- Duke University, Durham
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
피험자 모집 중2상
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10마일 거리
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
피험자 모집 중1/2상
- UNC School of Medicine, Division of Hematology, Chapel Hill · 10마일 거리
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
피험자 모집 중3상
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10마일 거리
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
피험자 모집 중관찰 연구건강한 지원자 환영
- Durham VA Medical Center, Durham
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
피험자 모집 중2상
- Research Site, Durham
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
피험자 모집 중1/2상
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill · 10마일 거리
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
피험자 모집 중1상
- University of North Carolina at Chapel Hill, Chapel Hill · 10마일 거리
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
피험자 모집 중1상
- Duke University Medical Center, Durham
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
피험자 모집 중
- North Carolina Basnight Cancer Hospital, Chapel Hill · 10마일 거리
Registry of Older Patients With Cancer
피험자 모집 중관찰 연구
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10마일 거리
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
피험자 모집 중1상
- University of North Carolina, Chapel Hill · 10마일 거리
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
피험자 모집 중4상
- Duke University Medical Center, Durham
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
피험자 모집 중4상
- Duke University Medical Center, Durham
Study of SGR-1505 in Mature B-Cell Neoplasms
피험자 모집 중1상
- Duke University, Durham
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
피험자 모집 중2상
- University of North Carolina /ID# 233313, Chapel Hill · 10마일 거리
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
피험자 모집 중2상
- The University of North Carolina at Chapel Hill, Chapel Hill · 10마일 거리
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
피험자 모집 중1상
- Duke University, Durham
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
피험자 모집 중관찰 연구
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10마일 거리
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
피험자 모집 중2상
- Durham VA Medical Center, Durham, NC, Durham
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
피험자 모집 중1상
- University of North Carolina, Chapel Hill · 10마일 거리
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
피험자 모집 중1상
- Duke University, Durham
다른 도시의 만성 림프구성 백혈병 시험
- Boston, MA연구 31개
- Columbus, OH연구 29개
- Washington, DC연구 22개
- Seattle, WA연구 21개
- Rochester, MN연구 19개
- New York City, NY연구 18개
- Houston, TX연구 17개
- Baldwin Park, CA연구 16개
- Milwaukee, WI연구 14개
- Chicago, IL연구 14개
- Cincinnati, OH연구 14개
- Nashville, TN연구 13개
Durham의 다른 연구
- 유방암연구 63개
- 암 (전체)연구 59개
- 비소세포폐암연구 39개
- 다발성 골수종연구 37개
- 전이성 암연구 33개
- 급성 골수성 백혈병연구 33개
- 폐암연구 32개
- 전립선암연구 32개
- 대장직장암연구 28개
- 난소암연구 27개
- 심부전연구 26개
- 췌장암연구 25개
ClinicalTrials.gov 출처, 2026. 10. 1. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.